RJA
BCRX icon

Raymond James & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Raymond James & Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,734
Closed -$169K – 3888
2022
Q4 		$169K Buy
+14,734
New +$184K ﹤0.01% 3510
2021
Q4 		– Sell
-18,283
Closed -$263K – 4143
2021
Q3 		$263K Sell
18,283
-889
-5% -$14K ﹤0.01% 3510
2021
Q2 		$303K Buy
+19,172
New +$260K ﹤0.01% 3433

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Raymond James & Associates's BCRX Position: Q1 2023 in Review

Raymond James & Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 14,734 shares — an estimated $169K sold.

Raymond James & Associates first reported a position in BCRX in Q2 2021 and held it in 3 quarters. The position peaked at $303K in Q2 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

  • Raymond James & Associates reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 14,734 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $169K.
  • Raymond James & Associates first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Raymond James & Associates's BioCryst Pharmaceuticals position peaked at $303K in Q2 2021.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.